<SEC-DOCUMENT>0001193125-22-206643.txt : 20220729
<SEC-HEADER>0001193125-22-206643.hdr.sgml : 20220729
<ACCEPTANCE-DATETIME>20220729161633
ACCESSION NUMBER:		0001193125-22-206643
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220729
DATE AS OF CHANGE:		20220729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263553
		FILM NUMBER:		221121030

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d339043d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-263553 <BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated July 29,
2022) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g339043g76w73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $75,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales
agreement, or the Sales Agreement, with SVB Securities LLC, or SVB Securities, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms
of the Sales Agreement, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to $75,000,000&nbsp;million through SVB Securities, acting as sales agent, pursuant to this prospectus supplement
and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol &#147;STTK.&#148; On
July&nbsp;25, 2022, the last reported sale price of our common stock as reported on Nasdaq was $4.24 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under
this prospectus supplement may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to terms of the Sales Agreement,
SVB Securities is not required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between
SVB Securities and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities will be entitled to a
commission of up to 3.0% of the gross sales price per share sold under the Sales Agreement. See &#147;Plan of Distribution&#148; beginning on page S-11 for additional information regarding SVB Securities&#146; compensation. In connection with the
sale of our common stock on our behalf, SVB Securities may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of SVB Securities may be deemed to be underwriting commissions or discounts. We have
also agreed to provide indemnification and contributions to SVB Securities against certain civil liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. See &#147;Plan of
Distribution&#148; beginning on page <FONT STYLE="white-space:nowrap">S-11</FONT> for additional information regarding the compensation to be paid to SVB Securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common
stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#supptoc339043_4">Risk Factors</A>&#148; on page S-6 of this prospectus supplement, and under similar headings
in the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SVB Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July
29, 2022 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_5">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_11">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc339043_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_2">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_7">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an offering of shares of our common stock. Before buying any of the common stock that we
are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find Additional Information&#148; and
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. Unless the context otherwise requires,
references in this prospectus supplement to &#147;Shattuck,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and &#147;ours&#148; refer to Shattuck Labs, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds to,
updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the accompanying prospectus, which gives more general information. Generally, when we refer to this prospectus,
we are referring to both parts of this document combined. To the extent the information contained in this prospectus supplement differs from or conflicts with the information contained in the accompanying prospectus or any document incorporated by
reference, the information in this prospectus supplement will control. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into
this prospectus supplement and the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and SVB Securities has not, authorized anyone to provide you with information different from that which is contained in or incorporated by
reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may give to you. No one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this
prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that any information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the
document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus, any related free writing prospectus, or any sale of our common
stock. Our business, financial condition, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of
the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference include trademarks, servicemarks and
tradenames owned by us or other companies. All trademarks, servicemarks and tradenames included or incorporated by reference in this prospectus supplement or the accompanying prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us and this offering and selected information contained elsewhere in or incorporated by reference into
this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of
our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus
supplement and the accompanying prospectus, and the information included in any free writing prospectus that we authorize for use in connection with this offering, including the information contained in and incorporated by reference under the
heading &#147;Risk Factors&#148; beginning on page S-6 of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the
accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an
innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural
characteristics that are not achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC, platform simultaneously inhibit checkpoint
molecules and activate costimulatory molecules with a single therapeutic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our ARC platform, we have developed a second novel platform
technology based upon our deep expertise in dual-sided fusion proteins. We call this our gamma delta T cell engager, or GADLEN, platform. Compounds derived from our proprietary GADLEN platform simultaneously activate gamma delta T cells and promote
antigen-dependent tumor cell killing with a single therapeutic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in 2016 in the State of Delaware. Our principal executive offices are located at 500 W. 5th Street, Suite 1200, Austin, TX 78701 and our
telephone number is (512) <FONT STYLE="white-space:nowrap">900-4690.</FONT> Our website is www.shattucklabs.com. The information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference
herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an early clinical-stage biotechnology company and have incurred significant losses since our inception,
and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require additional funding in order to complete development of our product candidates and commercialize
our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs, our efforts to
access manufacturing capacity and our commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require
us to relinquish rights to our technologies or product candidates. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Public health crises such as pandemics or other events could materially and adversely affect our business
operations, workforce, product development activities, research and development activities, preclinical and clinical trials, and financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ARC and GADLEN platforms are based on novel technologies that are unproven and may not result in approvable
or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our
technology platforms to develop and commercialize our product candidates, or may experience significant delays in doing so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product
candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may
change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our
product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties
that may delay or prevent marketing approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we experience delays or difficulties enrolling patients in our clinical trials, our research and development
efforts and business, financial condition, and results of operations could be materially and adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all,
our business will be substantially harmed. We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to manufacture biological materials and our product candidates. The manufacture of our
product candidates is complex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on patents and other intellectual property rights to protect our technology, including product candidates
from our ARC and GADLEN platforms, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are
otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement to have only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations disclosure; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports and other filings and
exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden parachute compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We will remain an
emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2025; (iii) the date on which we have issued more than
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the previous three years; and (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value
of our ordinary shares that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700.0&nbsp;million as of the prior June 30. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us</B> </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $75,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding after the offering</B> </P></TD>
<TD>Up to 60,070,692 shares of our common stock, assuming sales of 17,688,679 shares of our common stock in this offering at an assumed offering price of $4.24 per share, which was the last reported sale price of our common stock on Nasdaq on July
25, 2022. The actual number of shares issued will vary depending on the sales prices at which our common stock is sold under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Plan of Distribution</B> </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, SVB Securities. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>We intend to use the net proceeds from this offering for pipeline development, general corporate purposes and working capital. See &#147;Use of Proceeds&#148; on page S-10 of this prospectus supplement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#147;Risk Factors&#148; on page S-6 of this prospectus supplement, in the accompanying prospectus and
in the documents incorporated by reference into this prospectus supplement and any free writing prospectus that we authorize for use in connection with this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq symbol</B> </P></TD>
<TD>&#147;STTK&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 42,382,013 shares of our
common stock outstanding as of June&nbsp;30, 2022 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,899,926 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30, 2022
at a weighted-average exercise price of $9.04 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">310,727 shares of common stock issuable upon the vesting of restricted stock units outstanding as of
June&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,806,098 shares of common stock reserved for issuance pursuant to future equity awards under our 2020 Equity
Incentive Plan as of June&nbsp;30, 2022, as well as any shares reserved pursuant to provisions in this plan that automatically increase the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">811,850 shares of common stock reserved for issuance under our 2020 Employee Stock Purchase Plan as of
June&nbsp;30, 2022, as well as any shares reserved pursuant to provisions in this plan that automatically increase the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves risks. Before making an investment decision, you should carefully consider the risks and other information we include
or incorporate by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering. In particular, you should consider the risk factors
described under the heading &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as may be revised or supplemented by our subsequent Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or
superseded from time to time by other reports we file with the SEC in the future. In addition to those risk factors, there may be additional risks and uncertainties which are not currently known to us or that we currently deem immaterial. Our
business, financial condition or results of operations could be materially adversely affected by any of these risks. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience
future dilution as a result of future equity issuances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may at any time, including during the pendency of
this offering, offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities
in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per
share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. In addition, as of
June&nbsp;30, 2022, 3,899,926 shares of our common stock were issuable upon the exercise of options outstanding at a weighted-average exercise price of $9.04 per share, and 310,727 shares of our common stock were issuable upon the vesting of
restricted stock units outstanding. To the extent shares have been issued or are issued under these outstanding options at exercise prices lower than the price of our common stock in this offering, or outstanding restricted stock units have vested
or vest, you will incur further dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a significant number of shares of our common stock in the public markets, or the perception that
such sales could occur, could depress the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the
public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We may sell a significant number of shares of
our common stock at any time pursuant to this prospectus supplement and the accompanying prospectus or in one or more separate offerings. We cannot predict the effect that future sales of our common stock would have on the market price of our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will sell under the Sales Agreement, at any one time or in total, as well as the gross proceeds resulting
from those sales, is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion
to deliver a placement notice to SVB Securities at any time throughout the term of the Sales Agreement. The number of shares that are sold by SVB Securities under the Sales Agreement and upon delivery of a placement notice will fluctuate based on
the market price of the shares of common stock during the sales period and the limits we set with SVB Securities. Because the price of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not
possible to predict the number of shares that will ultimately be sold or the gross proceeds to be raised in connection with the sale of shares of common stock offered under this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of our cash and cash equivalents, including the net proceeds we
receive in this offering, and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents, including
the net proceeds we receive in this offering, to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock, and you will not have the opportunity as part of your
investment decision to assess whether the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the
price of our common stock to decline and delay the development of our product candidates. You will not have the opportunity to influence our decisions on how to use our cash and cash equivalents, including the net proceeds from this offering.
Pending their use to fund our operations, we may invest our cash and cash equivalents, including the net proceeds from this offering, in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings&#148; and investors who buy shares at different times will likely pay
different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may
experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, pricing and number of shares sold, and there is no maximum sales price. Pursuant to
the parameters set by our board of directors, there will be a minimum sales price for shares of our common stock sold in this offering, which will limit our ability to make sales if the public trading price of our common stock drops below that
minimum sales price. Such minimum sales price may be below the price paid by investors in this offering. Further, our board of directors will retain the ability to increase or decrease such minimum sales price in the future. Investors may experience
a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_5"></A>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We make &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act in this
prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein. Our forward-looking statements are subject to risks and uncertainties and include information about our current
expectations and possible or assumed future results of our operations. When we use words such as &#147;may,&#148; might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;forecast,&#148; &#147;projected,&#148; &#147;intend&#148; or similar expressions, or make statements regarding our
intent, belief, or current expectations, we are making forward-looking statements. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many
of which are beyond our control or are subject to change, actual results could be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements. Such business, economic
and competitive uncertainties include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress and expected results of our nonclinical studies, our clinical trials and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key executives and to identify, hire and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials
and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage, and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology platforms, including our ARC<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and GADLEN<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> product candidates and other product candidates, and the defense of such
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are
available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the market opportunity for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements and needs for additional financing, and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and associated public health guidance
measures.; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other risks more fully discussed in the &#147;Risk Factors&#148; section in this prospectus supplement, the
accompanying prospectus and the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under &#147;Risk Factors&#148; and elsewhere in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other
factors not currently anticipated may also materially and adversely affect our results of operations, cash flows and financial position. Readers should not place undue reliance on any such forward-looking statements, which are based on information
available to us on the date of this report or, if made elsewhere, as of the date made. We do not undertake, and expressly disclaim, any intention to update or alter any statements whether as a result of new information, future events or otherwise
except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue and sell up to $75,000,000 of our common stock from time to time. Because we are not required to sell any shares of our common stock under the
Sales Agreement, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the Sales Agreement as a source of
financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for pipeline development, general corporate purposes and working capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds, if any, from this offering.
Accordingly, we will retain broad discretion over the use of any such proceeds. Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a Sales Agreement with SVB Securities under which we may issue and sell up to $75,000,000 of shares of our common stock from time to time
through SVB Securities as our sales agent. Sales of our common stock, if any, will be made by any method that is deemed to be an &#147;at the market offering&#148; as defined in Rule 415 under the Securities Act, including sales made directly on or
through the Nasdaq Global Select Market, on or through any other existing trading market for the common stock or to or through a market maker. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB
Securities will offer our common stock subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and SVB Securities. We will designate the maximum number or amount of common stock to be sold
through SVB Securities on a daily basis or otherwise determine such maximum number or amount together with SVB Securities. Subject to the terms and conditions of the Sales Agreement, SVB Securities will use commercially reasonable efforts consistent
with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market to sell on our behalf all of the common stock requested to be sold by us. We may instruct SVB
Securities not to sell common stock if the sales cannot be effected at or above a minimum price designated by us in any such instruction. SVB Securities or we may suspend the offering of our common stock being made through SVB Securities under the
Sales Agreement upon proper notice to the other party. SVB Securities and we each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#146;s sole discretion at any time. The
offering of our common stock pursuant to the Sales Agreement will otherwise terminate upon the termination of the Sales Agreement as provided therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation payable to SVB Securities as sales agent will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold through it
pursuant to the Sales Agreement. We have also agreed to reimburse SVB Securities for certain actual outside legal expenses incurred by SVB Securities in connection with this offering, including SVB Securities&#146; counsel fees in an amount up to
$90,000, plus an additional amount of up to $25,000 in connection with each diligence bring-down thereafter. We estimate that the total expenses of the offering payable by us, excluding commissions payable to SVB Securities under the Sales
Agreement, will be approximately $550,000. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales of our
common stock, will equal our net proceeds for the sale of such common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities will provide written confirmation to us no later than the
next succeeding trading day on the Nasdaq Global Select Market after each day on which common stock is sold through it as sales agent under the Sales Agreement. Each confirmation will include the number or amount of shares sold through it as sales
agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us from such sales. We will report at least quarterly the number of shares of common stock sold through SVB
Securities under the Sales Agreement, the net proceeds to us and the compensation paid by us to SVB Securities in connection with the sales of common stock during the relevant period. Settlement for sales of common stock will occur, unless the
parties agree otherwise, on the second trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the common stock on our behalf pursuant to the Sales Agreement, SVB Securities may be deemed to be an &#147;underwriter&#148;
within the meaning of the Securities Act and the compensation paid to SVB Securities may be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to SVB Securities with
respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As sales agent, SVB Securities will not engage in any
transactions that stabilize our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed and traded on the Nasdaq Global Select Market under the symbol &#147;STTK.&#148;
The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities and/or its affiliates have
provided, and may in the future provide, various investment banking and other financial services for us for which services they have received, and may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California will pass upon the validity of the shares of common stock offered hereby. SVB Securities LLC
is being represented in connection with this offering by Latham&nbsp;&amp; Watkins LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Shattuck Labs, Inc. as of December&nbsp;31, 2021 and 2020, and for each of the years then ended, have been incorporated by
reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_11"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We also filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> including exhibits, under the Securities Act with respect to the securities offered by this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus are
a part of that registration statement, but do not contain all of the information included in the registration statement or the exhibits. You can find our public filings with the SEC on the internet at a web site maintained by the SEC located at
www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc339043_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities and Exchange Commission, or SEC, allows us to incorporate by reference much of the information we file with the SEC, which means that we can
disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement is considered to be part of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we are incorporating by reference future filings with the SEC, this prospectus supplement is continually updated and those future filings may modify
or supersede some of the information included or incorporated in this prospectus supplement. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement
or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following
the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed, except that we are not incorporating by reference any information furnished (and not filed) with the
SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036722000005/sttk-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021 filed on March&nbsp;15, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036722000015/sttk-20220331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarter ended March&nbsp;31, 2022 filed on May&nbsp;12, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312522172003/d330760d8k.htm">June&nbsp;10,
 2022</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036722000005/sttk-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1680367/000119312522113098/d148434ddef14a.htm">Schedule 14A</A> filed
on April&nbsp;21, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in or incorporated into our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1680367/000119312520263847/d939403d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on October&nbsp;5, 2020, including any amendment or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by contacting us, either orally or in writing, at the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500
W. 5th Street, Suite 1200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78701 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(512)&nbsp;900-4690</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at<I>&nbsp;www.shattucklabs.com</I>. Information about us, including our reports filed with the SEC, is available through that site.
Such reports are accessible at no charge through our website and are made available as soon as reasonably practicable after such material is filed with or furnished to the SEC. Our website and the information contained on that website, or connected
to that website, are not incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may read and copy any materials we file with the SEC at the SEC&#146;s website
mentioned under the heading &#147;Where You Can Find Additional Information.&#148; The information on the SEC&#146;s website is not incorporated by reference in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g339043g03a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT
SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may issue, in one or more series or classes, up to $150,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units, at prices and on terms that we will determine at the time of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will
provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free
writing prospectus may also add, update or change information contained in this prospectus. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. If information in any prospectus supplement is
inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will supersede the information in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, as well as any
documents incorporated by reference, before you invest in any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares of common stock are listed on
The Nasdaq Global Select Market under the symbol &#147;STTK.&#148; The last reported sale price of our common stock on The Nasdaq Global Select Market on March&nbsp;14, 2022 was $4.29 per share. We recommend that you obtain current market quotations
for our common stock prior to making an investment decision. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading </B><B><I>&#147;</I></B><B><A HREF="#toc339043_4">Risk Factors</A>&#148; contained in this prospectus beginning on
page&nbsp;5&nbsp;and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
dated July&nbsp;29, 2022 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_2">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_7">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc339043_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission (the &#147;SEC&#148; or the &#147;Commission&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one
or more offerings up to a total dollar amount of $150,000,000. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the
terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we
may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read both this prospectus and any
prospectus supplement together with additional information under the headings &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus
and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. This prospectus, any applicable
supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any
applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document
incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Shattuck Labs,&#148;
&#147;Shattuck,&#148; or the &#147;company&#148; refer to Shattuck Labs, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains &#147;forward-looking statements&#148; within the meaning
of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements, other than statements of
historical facts contained in this prospectus, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to acquisitions, business trends
and other information referred to in the section entitled &#147;Risk Factors&#148; in this prospectus and the sections entitled &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, which is incorporated by reference herein, are forward-looking statements. Forward-looking
statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;objective,&#148;
&#147;intend,&#148; &#147;should,&#148; &#147;could,&#148; &#147;can,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;believe,&#148; &#147;design,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;target,&#148; &#147;forecast,&#148; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current
views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the
forward-looking statements contained in this prospectus. Such risks, uncertainties and other important factors include, among others, the risks, uncertainties and factors set forth in &#147;Risk Factors,&#148; and the following risks, uncertainties
and factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress and expected results of our nonclinical studies, our clinical trials and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key executives and to identify, hire and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials
and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology platforms, including our Agonist Redirected Checkpoint and GADLEN<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> product candidates and other product candidates, including the defense of such intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are
available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the market opportunity for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements and needs for additional financing and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and associated public health guidance
measures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There may be other factors that may cause our actual results to differ materially from the forward-looking
statements, including factors disclosed in &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the year ended December&nbsp;31, 2021, which is incorporated by reference herein. You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We caution you that the risks, uncertainties and other factors referred to above and elsewhere in this prospectus may not contain all of the
risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will
realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements contained in this prospectus, any accompanying prospectus supplement, information incorporated by reference
herein or therein, and any related free-writing prospectus speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future
events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of
biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that are not achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds
derived from our proprietary Agonist Redirected Checkpoint, or ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We were
incorporated in 2016 in the State of Delaware. Our principal executive offices are located at 500 W. 5th Street, Suite 1200, Austin, TX 78701 and our telephone number is (512) <FONT STYLE="white-space:nowrap">900-4690.</FONT> Our website is
<I>www.shattucklabs.com</I>. The information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk&nbsp;factors and other information contained in or
incorporated by reference into any accompanying prospectus supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected by any of
these risks. The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For more information about our SEC filings, please see &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of
Certain Information by Reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in
a prospectus supplement accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used to advance our ongoing and planned clinical trials and to develop and advance additional
product candidates derived from our platforms, as well as for working capital and general corporate purposes. We may also use a portion of the proceeds to license, acquire, or invest in complementary businesses, technology, products, or assets.
However, we have no current commitments to do so. Our expected use of proceeds from the sale of the securities offered hereby represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we
cannot predict with certainty all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will actually spend on the uses set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we may invest the proceeds in a variety of capital preservation investments, including
interest-bearing, investment-grade securities, certificates of deposit, or government securities. When we offer and sell the securities to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended
use of the proceeds, if any, received from the sale of such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and future earnings, if
any, to fund the operations and the further development and expansion of our business. We have no present intention to pay cash dividends on our common stock. Any determination to pay dividends to holders of our common stock will be at the
discretion of our board of directors (the &#147;Board&#148;) and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements,
restrictions in the agreements governing any indebtedness we may enter into, our business prospects, and other factors that our Board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_7"></A>SECURITIES WE MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be
complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_8"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following is a summary of
the material terms of our capital stock, as well as other material terms of our second amended and restated certificate of incorporation (&#147;certificate of incorporation&#148;) and amended and restated bylaws (&#147;bylaws&#148;) and certain
provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and our bylaws. For more information on how you can obtain our certificate of
incorporation and our bylaws, see the heading &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 300,000,000 shares of common stock, $0.0001 par value per&nbsp;share, and 10,000,000 shares of &#147;blank check&#148; preferred stock, $0.0001 par value per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation authorizes the issuance of up to 300,000,000 shares of our common stock. All outstanding shares of our common stock are validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders, and our certificate of
incorporation does not provide for cumulative voting in the election of directors. The holders of our common stock will receive ratably any dividends declared by our Board out of funds legally available therefor. In the event of our liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of our common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under the terms of our
certificate of incorporation, our Board has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in
each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of
any such series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred
stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other
corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common
stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are party to a second amended and restated investors&#146; rights agreement, effective as of June&nbsp;12, 2020, which provides that certain
of our stockholders have registration rights described below. The registration of shares of our common stock pursuant to the exercise of these registration rights would enable holders to sell these shares without restriction under the Securities Act
when the registration statement is declared effective. We will pay all expenses related to any demand, piggyback, or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration described below, with the exception of underwriting discounts and
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The registration rights described below will expire upon the earliest to occur of: (i)&nbsp;October&nbsp;14, 2025 or
(ii)&nbsp;with respect to any particular holder, at the time that such holder can sell all its registrable securities under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rule 144 or another similar exemption under the Securities Act without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The holders of registrable securities are entitled to certain demand registration rights. At any time, (x)&nbsp;holders who are major investors
and hold a majority of the registrable securities then outstanding and held by major investors or (y)&nbsp;holders who are major investors and hold at least 70% of the registrable securities then outstanding may request that we register all or a
portion of their registrable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to certain specified exceptions, if we propose to register any of our securities under the Securities Act either for our own account or
for the account of other stockholders, the holders of shares having registration rights are entitled to written notice and certain &#147;piggyback&#148; registration rights allowing them to include their shares in our registration statement. These
registration rights are subject to specified conditions and limitations, including the right of the underwriters, in their sole discretion, to limit the number of shares included in any such offering under certain circumstances, but not below 30% of
the total amount of securities included in such offering, unless any registrable securities which are not key holder registerable securities be excluded from such underwriting unless all key holder registrable securities are first excluded from such
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At any time after we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> and subject to
limitations and conditions, (x)&nbsp;holders who hold are major investors and hold a majority of the registrable securities then outstanding and held by major investors or (y)&nbsp;holders who are major investors and hold at least 70% of the
registrable securities then outstanding may make a written request that we prepare and file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act covering their shares, so long as the aggregate price
to the public, net of the underwriters&#146; discounts and commissions, is at least $5,000,000. We will prepare and file the Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration as requested, unless, in the good faith judgment of our Board,
such registration would be seriously detrimental to the company and its stockholders and filing should be deferred. We may defer only once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period, and such deferral shall not exceed 90 days
after receipt of the request. In addition, we are not obligated to prepare or file any of these registration statements (i)&nbsp;within 90 days after the effective date of a registration statement pursuant to demand or piggyback registration rights
or (ii)&nbsp;if two of these registrations have been completed within any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover
Effects of Our Certificate of Incorporation, Bylaws and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our amended bylaws include a
number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our
Board rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Issuance of undesignated preferred stock</B>: Under our certificate of incorporation, our Board has the
authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but
unissued shares of preferred stock enables our Board to make it more difficult to attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Classified board</B>: Our certificate of incorporation establishes a classified Board consisting of three
classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision
may have the effect of delaying a change in control of our Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Election and removal of directors and board vacancies</B>: Our certificate of incorporation provides that
directors will be elected by a plurality vote. Our certificate of incorporation and bylaws also provide that our Board has the right to increase or decrease the size of the Board and to fill vacancies on the Board. Directors may be removed only for
cause by the affirmative vote of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast in an annual election of directors. Only our Board is authorized to fill vacant directorships. In addition the number
of directors constituting our Board may be set only by resolution adopted by a majority vote of the directors then in office. These provisions prevent stockholders from increasing the size of our Board and gaining control of our Board by filling the
resulting vacancies with its own nominees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Requirements for advance notification of stockholder nominations and proposals</B>: Our bylaws establish
advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder&#146;s notice. Business that may be
conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to
nominate directors at annual meetings of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No written consent of stockholders</B>: Our certificate of incorporation provides that all stockholder actions
be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would
prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No stockholder ability to call special meetings</B>: Our certificate of incorporation and bylaws provide that
only our Board may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Amendments to certificate of incorporation and bylaws</B>: Any amendment to our certificate of incorporation
must be approved by a majority of our Board as well as, if required by law or our certificate of incorporation, a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to
vote thereon as a class, except that the amendment of provisions to Board classification, stockholder action, certificate amendments, and liability of directors must be approved by not less than 66 2/3% of the outstanding shares entitled to vote on
the amendment, voting together as a single class. Any amendment to our bylaws will be required to be approved by either a majority of our Board or not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, voting together as
a single class. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">These provisions are designed to enhance the likelihood of continued stability in the composition of
our Board and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of our company and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to
discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price
of our shares that could result from actual or rumored takeover attempts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware General Corporation Law Section&nbsp;203
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As a Delaware corporation, we are also subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General
Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in
which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding disinterested shares. The application of Section&nbsp;203 of the Delaware General Corporation Law could also have the
effect of delaying or preventing a change of control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum Selection Clause </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum to the fullest extent permitted by law for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders;
(3)&nbsp;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of
incorporation or bylaws; or (5)&nbsp;any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State
of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#146;s having jurisdiction over indispensable parties named as defendants. In addition, our certificate of incorporation
provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but the forum selection provisions will not apply to claims brought
to enforce a duty or liability created by the Exchange Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may
have the effect of discouraging lawsuits against us or our directors or officers. Although our certificate of incorporation contains the choice of forum provisions described above, it is possible that a court could find that such provisions are
inapplicable for a particular claim or action or that such provisions are unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp; Trust Company, LLC serves as the transfer agent and registrar for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on
The Nasdaq Global Select Market under the symbol &#147;STTK.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series
of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate
whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price
of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have summarized below the material provisions of the indenture, or indicated which material provisions will be described in the related
prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in this prospectus. We have
included the form of the indenture as an exhibit to our registration statement of which this prospectus is a part, and it is incorporated into this prospectus by reference. Because the summary in this prospectus and in any prospectus supplement does
not contain all of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus or in any applicable prospectus supplement. Please read
&#147;Where You Can Find Additional Information&#148; in this prospectus to find out how you can obtain a copy of those documents. References below to an &#147;indenture&#148; are references to the indenture, as supplemented, under which a
particular series of debt securities is issued. As used under this caption, the term &#147;debt securities&#148; includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
indenture: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not limit the amount of debt securities that we may issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allows us to issue debt securities in one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not require us to issue all of the debt securities of a series at the same time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allows us to reopen a series to issue additional debt securities without the consent of the holders of the debt
securities of such series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for each offering of debt securities will provide the following
terms, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether they are senior, senior subordinated or subordinated debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities being offered and any limit on their aggregate principal
amount, and, if the series is to be issued at a discount from its face amount, the method of computing the accretion of such discount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other
than the full principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible
into common stock or preferred stock or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the terms on which such debt securities are convertible, including the initial conversion price
or rate or the method of calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at our option, the conversion or exchange period, and any other
provision in relation thereto, and any applicable limitations on the ownership or transferability of common stock or preferred stock received on conversion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities
will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or
rates is determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, from which interest will accrue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payment dates, or the method by which we will determine those dates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons to whom interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the basis upon which interest will be calculated if other than that of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any collateral securing the performance of our obligations under the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, premium, if any, and interest on, the debt securities will be
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the debt securities may be surrendered for registration of transfer or conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be
served; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions regarding our right to redeem or purchase debt securities or the right of holders to require us to
redeem or purchase debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any right or obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or
analogous provision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies (including any composite currency) in which the debt securities are denominated and
payable if other than United States dollars, and the currency or currencies (including any composite currency) in which principal, premium, if any, and interest, if any, will be payable, and if such payments may be made in a currency other than that
in which the debt securities are denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between the currency in which such securities are denominated and the currency in which such
securities or any of them may be paid, and any additions to, modifications of or deletions from the terms of the debt securities to provide for or to facilitate the issuance of debt securities denominated or payable in a currency other than U.S.
dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of, premium, if any, or interest on, the debt securities may be
determined according to an index, formula or other method and how such amounts will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered form, bearer form or both, and the terms of these forms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in whole or in part in the form of a global security and, if
applicable, the identity of the depositary for such global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provision for electronic issuance of the debt securities or issuance of the debt securities in uncertificated
form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and upon what terms the debt securities of such series may be defeased or discharged, if different from
the provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to holders of securities upon the occurrence of such events as specified
in the applicable prospectus supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any deletions from, modifications of, or additions to our events of default or covenants or other provisions set
forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities, which may be different from the terms set forth in this
prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue debt securities at a discount below their principal amount and provide for less than the
entire principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#147;original issue discount securities.&#148; The applicable
prospectus supplement will describe the United States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Delaware General Corporation Law nor our governing instruments define the term
&#147;substantially all&#148; as it relates to the sale of assets. Additionally, Delaware cases interpreting the term &#147;substantially all&#148; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a
sale of &#147;substantially all&#148; of our assets has occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will also describe any material covenants to which a series of debt securities will be subject and the
applicability of those covenants to any of our subsidiaries to be restricted thereby, which are referred to herein as &#147;restricted subsidiaries.&#148; The applicable prospectus supplement will also describe provisions for restricted subsidiaries
to cease to be restricted by those covenants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, when we refer to &#147;events of default&#148; as defined in the indentures with
respect to any series of debt securities, we mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay interest on any debt security of such series when the same becomes due and payable and the
continuance of any such failure for a period of 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay the principal or premium of any debt security of such series when the same becomes due and
payable at maturity, upon acceleration, redemption or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure or the failure of any restricted subsidiary to comply with any of its agreements or covenants in, or
provisions of, the debt securities of such series or the indenture (as they relate thereto) and such failure continues for a period of 60 days after our receipt of notice of the default from the trustee or from the holders of at least
25&nbsp;percent in aggregate principal amount of the then outstanding debt securities of that series (except in the case of a default with respect to the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or
other disposition of all or substantially all of the assets of us (or any other provision specified in the applicable supplemental indenture or authorizing resolution), which will constitute an event of default with notice but without passage of
time); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy, insolvency or reorganization occur with respect to Shattuck Labs or any restricted
subsidiary of Shattuck Labs that is a significant subsidiary (as defined in the indenture). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If an event of default
occurs and is continuing with respect to debt securities of any series outstanding, then the trustee or the holders of 25% or more in principal amount of the outstanding debt securities of that series will have the right to declare the principal
amount of all the debt securities of that series to be due and payable immediately. However, the holders of at least a majority in principal amount of outstanding debt securities of such series may rescind and annul such declaration and its
consequences, except an acceleration due to nonpayment of principal or interest on such series, if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to such series have been cured or
waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture also provides that the holders of at least a majority in principal amount of the outstanding debt securities of any
series, by notice to the trustee, may, on behalf of all holders, waive any existing default and its consequences with respect to such series of debt securities, other than any event of default in payment of principal or interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will require the trustee to give notice to the holders of debt securities within 90 days after the trustee obtains knowledge of
a default that has occurred and is continuing. However, the trustee may withhold notice to the holders of any series of debt securities of any default, except a default in payment of principal or interest, if any, with respect to such series of debt
securities, if the trustee considers it in the interest of the holders of such series of debt securities to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the outstanding principal amount of the debt securities of any
series will have the right to direct the time, method and place of conducting any proceedings for any remedy available to the trustee with respect to such series, subject to limitations specified in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment, Supplement and Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Without notice to or the consent of any holder, we and the trustee may amend or supplement the indenture or the debt securities of a series:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, omission, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or
other disposition of all or substantially all of our assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide that specific provisions of the indenture shall not apply to a series of debt securities not
previously issued or to make a change to specific provisions of the indenture that only applies to any series of debt securities not previously issued or to additional debt securities of a series not previously issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to create a series and establish its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to release a guarantor in respect of any series which, in accordance with the terms of the indenture applicable
to such series, ceases to be liable in respect of its guarantee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add a guarantor subsidiary in respect of any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to secure any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to the covenants of Shattuck Labs for the benefit of the holders or surrender any right or power conferred
upon Shattuck Labs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to appoint a successor trustee with respect to the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of holders; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to conform the provisions of the indenture to the final offering document in respect of any series of debt
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will provide that we and the trustee may amend or supplement any provision of the debt
securities of a series or of the indenture relating to such series with the written consent of the holders of at least a majority in principal amount of the outstanding debt securities of such series. However, without the consent of each holder of a
debt security the terms of which are directly amended, supplemented or waived, an amendment, supplement or waiver may not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities of such series whose holders must consent to an amendment, supplement or
waiver; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest, including defaulted interest;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or extend the fixed maturity of any debt security or alter the provisions with respect to
redemptions or mandatory offers to repurchase debt securities of a series in a manner adverse to holders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that adversely affects any right of a holder to convert or exchange any debt security into or for
shares of our common stock or other securities, cash or other property in accordance with the terms of such security; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the ranking or priority of the debt securities of the relevant series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">release any guarantor of any series from any of its obligations under its guarantee or the indenture otherwise
than in accordance with the terms of the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to any provision of the indenture relating to the waiver of existing defaults, the rights of
holders to receive payment of principal and interest on the debt securities, or to the provisions regarding amending or supplementing the indenture or the debt securities of a particular series with the written consent of the holders of such series,
except to increase the percentage required for modification or waiver or to provide for consent of each affected holder of debt securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a continuing default or event of default in the payment of principal of or interest on the debt securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any debt security payable at a place or in money other than that stated in the debt security, or impair the
right of any holder of a debt security to bring suit as permitted by the indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The holders of a majority in
aggregate principal amount of the outstanding debt securities of such series may, on behalf of all holders of debt securities of that series, waive any existing default under, or compliance with, any provision of the debt securities of a particular
series or of the indenture relating to a particular series of debt securities, other than any event of default in payment of interest or principal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Defeasance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
indenture will permit us to terminate all our respective obligations under the indenture as they relate to any particular series of debt securities, other than the obligation to pay interest, if any, on and the principal of the debt securities of
such series and certain other obligations, at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been
the case otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will also permit us to terminate all of our respective obligations under the
indenture as they relate to any particular series of debt securities, including the obligations to pay interest, if any, on and the principal of the debt securities of such series and certain other obligations, at any time by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
(A)&nbsp;we have received from, or there has been published by, the Internal Revenue Service a ruling, or (B)&nbsp;since the date such series of debt securities were originally issued, there has been a change in the applicable federal income tax
law, in either case to the effect that, and based thereon such opinion of counsel shall state that, holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to
federal income tax on the same amount and in the same manner and at the same times as would have been the case otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the indenture will permit us to terminate substantially all our respective obligations under the indenture as they relate to a
particular series of debt securities by depositing with the trustee money or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government obligations sufficient to pay all principal and interest on such series at its maturity or redemption date if the debt securities of such series will become due and payable at maturity
within one year or are to be called for redemption within one year of the deposit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer and Exchange </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A holder will be able to transfer or exchange debt securities only in accordance with the indenture. The registrar may require a holder, among
other things, to furnish appropriate endorsements and transfer documents, and to pay any taxes and fees required by law or permitted by the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concerning the Trustee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will contain limitations on the rights of the trustee, should it become our creditor, to obtain payment of claims in specified
cases or to realize on property received in respect of any such claim as security or otherwise. The indenture will permit the trustee to engage in other transactions; however, if it acquires any conflicting interest, it must eliminate such conflict
or resign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will provide that in case an event of default occurs and is not cured, the trustee will be required, in the
exercise of its power, to use the degree of care of a prudent person in similar circumstances in the conduct of such person&#146;s own affairs. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the
indenture at the request or direction of any of the holders pursuant to the indenture, unless such holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be
incurred by it in compliance with such request or direction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No Recourse Against Others </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indenture will provide that there is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to
any debt security against any of our or our successor&#146;s past, present or future stockholders, employees, officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
laws of the State of New York will govern the indenture and the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series, from time to time. We may
issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If we issue warrants, they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which
are contracts between us and an agent for the holders of the warrants. We urge you to read the prospectus supplement related to any series of warrants we may offer, as well as the complete warrant agreement and warrant certificate that contain the
terms of the warrants. If we issue warrants, forms of warrant agreements and warrant certificates relating to warrants for the purchase of common stock, preferred stock and debt securities will be incorporated by reference into the registration
statement of which this prospectus is a part from reports we would subsequently file with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may
evidence each series of units by unit certificates that we will issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit
agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following description, together with the
additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may
authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including,
without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain United States federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule
415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of The Nasdaq Global Select Market or any other securities exchange or quotation or
trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker otherwise than on The Nasdaq Global Select Market or such other securities exchanges
or quotation or trading services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Such at the market offerings, if any, may be conducted by underwriters acting as
principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided
to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options under which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may change from time to time. We may use
underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will
name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis
for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to offerings pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with
respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All securities we offer, other than our shares of common stock, will be new issues of securities with no established trading market. Any
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with
Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in the
securities on The Nasdaq Global Select Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids
are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP,
San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The financial statements of Shattuck Labs, Inc. as of December 31, 2021 and 2020, and for the years then ended, have been incorporated by
reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_12"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC, and we have filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of
the information included in the registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and
schedules and our reports, proxies, information statements and other information filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our filings are available to the
public on the Internet, through a database maintained by the SEC at <I>www.sec.gov</I>. We also maintain a website at <I>www.shattucklabs.com</I>. We have included our website address for the information of prospective investors and do not intend it
to be an active link to our website. Information contained on our website does not constitute a part of this prospectus or any applicable prospectus supplement (or any document incorporated by reference herein or therein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc339043_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may
modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any
document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the
registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed, except that we are not incorporating by reference any information
furnished (and not filed) with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of Form
<FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036722000005/sttk-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021 filed with the SEC on March&nbsp;15, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1680367/000119312521126933/d620528ddef14a.htm">Definitive Proxy
 Statement</A> on Schedule 14A filed April&nbsp;22, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/0001680367/000119312520263847/d939403d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on October&nbsp;5, 2020, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02, Item 7.01 or Item
9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of
the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These
documents include, without limitation, Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT>
as well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by contacting us, either orally or in writing, at the
following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 W. 5th Street, Suite 1200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78701 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(512) <FONT
STYLE="white-space:nowrap">900-4690</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We maintain a website at <I>www.shattucklabs.com</I>. Information about us, including our
reports filed with the SEC, is available through that site. Such reports are accessible at no charge through our website and are made available as soon as reasonably practicable after such material is filed with or furnished to the SEC. Our website
and the information contained on that website, or connected to that website, are not incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You
may read and copy any materials we file with the SEC at the SEC&#146;s website mentioned under the heading &#147;Where You Can Find Additional Information.&#148; The information on the SEC&#146;s website is not incorporated by reference in this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:150pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g339043g76w73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $75,000,000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SVB Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July 29, 2022 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g339043g03a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339043g03a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $UZ^25@X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          $J   $_     8 9P P #, 80 P #,    !
M          $             !/P   $J                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $J     %)G:'1L;VYG   $_     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !*@    !29VAT;&]N9P  !/P    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     4X0DE-! P     "0H    !
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M" D*"Q   00!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( %\!F ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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ML%R\0.49=Q_Y.-HZ]TK1--DL#I2Q0RS+-[1!#(758UV&*0J68JS%G7.?>"^
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MW:BFD)E,,P3;&5!B;>RY7=[_ $MTG<]3R70CN8[2&U6/?*Z-(6>4ML1$4C.
MA9B6&!C ).!(/IWWEBW4EIS"=T89&L(-!FL&9(CP+1C&3Z^766<VEM8$GVG.
M$1\*TKID9#A<X)VC:82JQ[5YQW%O/:3RVUS'VYH7*.H8,#YJZL/%)$*NA(!*
ML,JIR!XVLZ5/HNI76F7#I)+;,@+QYV.LD:2QL >1NC=25/*DD<XK-7.&O+IQ
M2ODCVB8\CU1K!L<][E_)K6(KG*O\2(BKQ2M9C:/VBD%7LC+L-TGTJW&U,?QB
MXL:L&42\ZEU,FX!6S"076T>CI<(R5\2MF&&I(1),]"O \2E$,CU&U49S]_V]
M1\> >!XGCP_[8EW/_@"V?\X>5_\ ZFXX^S_U3)_OY?$#U^OQ'IBO08=]HXD"
MS#'J;<72#>:_QJYL(T67>UV>S;&S@1#2!QSV$>DN\$QUED*'[GNF&&R$]S6J
MQG<CFHJHSCQQSG'CX#US\/'PQZ&MG6NGP[6O@VE>=DJ!90XT^#)'W]N1#F!9
M(C'9W1%\#!(PC>Z(OBY.Z(O%95%OKBZEI71]TN;1ZBX6(1\\DZZ%B1!XI*NB
M8\"V_2?.\8PUZ/N!5MN2'\-F1.L&JVND^^^(V,J"0RF&H?OC/Z5'WTQ_4&L/
M4*UQL;/;'5L+5A,#S:)B(ZR%EI\M99LDT4*Y6<^4?'\?=%>QTM8_QV@D-<C$
M)[R*Y6(I5F7%*J;]3WU,+/T\ :H-7:@@;5_9*+D8RMFYI(Q'[G2A97N:YB@Q
MK(?F_*^<J*CDC>U[:=E)Y_A5&><<>''W\//]O.<'2CO$_4KTZ:DWO*QP.(2-
MG8G'R8N- LWW0:=QY4N-\,=H2#6OFM:D9'^\Z!%55>K?:3Q[JH#D9^?]ZD)Q
M4UA#J/WUA73)I/8.[\_DL!CN!T,BT=&]YH9%Q9O5L:EH8+G->JSKJU-$KHR-
M&56/D>ZHW,&Y.*@D#QJB[I+^T$T&_-_8%I[9FC:K4&.Y]8DQ^#GH]E&R*/69
M#+$],?BV<"5AU"(,"VL$%5DG?>")"D2XYBC='0SQJ@$D_#Y'/P\?\9\/(YK9
M _/\N*RJHOU*_4SS'H)R?6>/XQT_%W.'/Z&YN94X>4VF/)2$J[ 4%D11U^(9
M*R1\EI%-YD+%<SQ\4&]%\D5!/('J#CC[^_3SJ_E_:0-G5\<LN=T.I"BA1%-)
ME[2R"/'$BN1J.(<VK&"8BN5K45[D[N<B)W5>* Y/@1QDY'[Y\?S_ #KCUWVD
MS8=NPI*CHFCV@PN:PSZ[;%Y-8%[D\FM*Z-JXK6.5$56HY6JJ)W1.W%,\\\Y]
M/_?F?H?$U*_HV];+8G5-U(:VT1==)!]=5F>3;:)*S)V=7ELVE2MH+6Z85:^7
MKVFCR$D$KF1$:2RC(SW_ #1SW-0;E0"V<''Z_IGTX\L?$5UO5OZX&Q^FCJ-V
MKHJGZ0CY_6ZYOXU-#S%N>7M6V^'(IJNU66E?%UW;@C>#[%T;P%92VJH//W$5
MZL8J2<9/D/@<_P#?Z8\SQ48+'[2;L&H03K;HHBU;3*Y NL=LW<)"JWLKD&LG
M5XD>K45%<C>ZHBHJ]D5.*9/I^GECGP/Z_D#XURXOVC_9\Z.*7"Z&UF1#M\@2
MHNT<AD1S-1RM5PC!U8\9&HYKF]V.5/)%3\T7D\?'X<_]<_I49/PXY/R^6<CX
MYX\\BK2_3/\ 4JR_K[N=NU>4:"+I9FLJS#K"%))D]GD/Z0NRF5D48X4988EC
M*1?NY*,3U<)\Q2_,[/:%!M4C_K]_^N*D$DD8X'G^7&/WK*7J6==T_P!/[3.)
M;7K]:Q-H&R?84+!W4DS*38F*&.717ERMDV>"BOW'>Q:=L=(JQ1-<AU)[Z*-&
M/BASQCY>&?+@_G]BLB= /5I+ZV>FO&=_S<'C:\D9!?953.QB+?ER4,5,;N3U
M39#;4U32O*LM ^\X:P!H%7>"/(B>2J#Y@_+_ --32XJ:H6R;UHKK'^OZ3T3-
MZ?:N5!C[G@ZG_9#78\L4MP9AXH5O/T:3#"!0@_D*Y('WTK7>'99:=^Z*@GG'
M^3Q]_0>)/@#?3Q4U 3U"^OK"/3^U-2;"R;%K+.K_ "_(78SAN'UL\-2MG/!"
M)8SY4^U/&F-KZVOB#1QSLARBO,>.$85<7NBHS]_4#]_\523'^T?[-GA9+K>A
MI\N"=%=&DQ]I9!)"4:.<SR8<&JU"3\37-51JJ(Y%;W547CCZ_/\ ;'[U!)'C
MCPS_ .'/B!\.?ASC]OVQIMCZ]^A*3]$_OEY+]/X>_P#S*?\ @_U^/K]_?C^F
M:9/'Q/ICC/Q.?#GSJQKTWO5\P_KZSG)M5V&JY^IMA4>.&RR!!;DP\MI;RFAR
MXL*S^-8K34$N--KRS8CR /7>V4)O(9O,;F<??W]_.I!S\O7U]?OSJY'BIJA[
MU#_6;NNACJ,9HB!T_P!7LB._"L7RY<EE[&EXP9'Y%*MHSH/W6'#;QGC$2L1[
M9'SNYE,J*(?@BN5!./3./#^W'SXJ\]+2(&I;<V$B-70F5[+&9)ER!@B0X_QT
MD&+(E&48A  Q7.(8BL8UC5>Y6IW[*FJ!>J?U\]8:NVK%U+TSZM-U0VX+ U+<
M7E1DTNBQ^3?)(^*&GPLM=C63R\P(IVN8^?!CBK3.5B5LB>Q7$:K'=X8^!^A\
MQY_OD8QR#5MO2MLWJ&VYKX&;]0&BZ3I^LK@<>50X*#.I69Y0&O,/W$D94-^,
MT$6@F%:X;AU+2S9\=%<RQ9"DM?&:X^OS_;'[U(SYXQ^OPSY?.O=Y/H36>7Y8
M#,[RD)(N1$C&.@YA@PK L3Q]A]A$8J,D*UK&,?V<Q"C8UA4>B*BTIU-_I\_"
M_J[K&/KG6M$FEUL26DUVL%]/;V&IS605;>74;2,A9Y%CCBB=E>+NQQ1I)O .
M=HL.L->TW37TJUNPMJ0XCW1J\T"R9WK!*>4!+,PR&VLQ*XK,:(B(B(B(B(B(
MB)V1$3Z(B(GT1$3\DY=0 4!5 "@      #   X  X ' %:QX^-159U>:T?M%
MNL$B7B2'72X\F0N!%2F^]D*Z/[*L63\] _+:L3Y"Q?%"_B5J!_=>4C%^//2,
MO5K]+"VU%434GTDZPRPBR]MCE-NP,1D]I$'M(-N)3'N+^]V^U[];RW0.LKHO
M\9[EKM]G%V;3>_M'8(#!MP0Q;NV1)M[@PO!(;W:RWN+5='N; ;C!+XI8@;#V
M9$&R Q"R*JTB.5\.P")SQL,HG*\9 />UA@%*)7,5R/;9?5?35IU7HT^DW4C0
M%GCGMKE 7:VNH<]N;M[T65=K/')&S -'(V"CA'77=#UBXT+48=0MU5VC#)+$
MQPLT+X$D9;!*YP"& RK*#@C(-7M9Z9>:R,D$/(=A8R+%!RFNDRZF)9ENY<)I
M/)PH\&4 $.)*,-O@I"SCAC.?YM9,0:L)3.G?@[K<,Z17.I:<EJKKW+B#ORRM
M'EB>S \<0[I 48DD5$+%@TH3:]JS_BEIXMG-OIUV;LH=B3/"L"2$  O(KN[(
MIYPL:EP,'83D2?ZM]Y%Z2]0X;C&LZV&"ZLV)C6,/F,21$H*>DA"218OCO16S
M)?9\<$81E0*E*:27R0#0&LKJ/5/]JZ9IFD:0%BD:/LQ2-MD-M:VZ!3($?(>6
M5V 0E6C7$A9>$4ZATGH@ZMU>]N]4E=HHS[3<!/=:YGG=BL>X?\<8PS.5][ 5
M5QN+"L/6'J-;^Q/.*J9L')F9YAIYX07M-.J*.N.&O.]!GE5<ZHK(9@2HC'>^
M)ADD *HE$\78BO37M-ZFUF)TGEO'O(U]Z:WF2(+.O ;8R0J\4N%_EF,F,/XQ
M,&8&P=4Z"T*XLY$L;7V*ZVGL31RSN-X!*K(DLKJR,?=;&& .0W JR3K:Z,&=
M5]1C.78A?0L>S['ZE\2O);B.ZIOJ*8Y]@&KFEC>9J^1'E2"GB3&1Y+/*08$@
M2,<PP+#U'3Y;J2&_M2#((0DEO*Q02Q>](A1N4CG1F*Y9=LBL$>1 B,*YZ3ZJ
M_P!N27%I=PM-932AW,1'<@G3"-(H.!(C*H5ER"-H9<DE6B?TH^EQEF!;0Q[9
MNZ<@QXL;"[,-S0XGCI9-B^RN83D+6S;.Q(.(")#KY+1S!QXXY)I4@(VD6,)B
M^[C:6=Y-M%U"MI$LB.Z&999I#&P=%4PDQQH7"LS%V8A3&(@&[@V+J/\ $&UN
M[">QTJ*8M=1&&6XF58UCBD!6540[F=W0E,G8J@[@6/NBT/J/ZAL&Z8M8S]HY
M\.SE54>Q@TT"KI@"/:W%S9)()%KH39!H\5A'1X<R40LJ0  H\4SG/\D:QWNL
MS!HHT0R232=N-1P-VQY&9VP0B*D;L6(.2 J@LR@UYHFC76NWRV-H8U<QO,\D
MI(CBB0JK.VT,Q]YT4!5))8>0)'F>E;JNUWU;8+9YM@,.\I_N*[)07M#D0(H;
M2MGI%!- YSH,F9#D19<60PD<X)#N[F&$1@R"<U)8O'.]M,JI/''%,R*_<5HI
MC(L<J-A6*-)#,@WI&Y:)LH!@GL=0]/7G3EU';7;Q2B>+NPS0[MCJ&*L"'565
MU.-RD< @@D&N3U)]).D>K&CH*+<N-R[@>+3I4_'[&JM9=+;UA)XP"L @G1%[
MOB3V18J2HIQE$]T8!&M843'IV+:YN;.;OVEQ);2E.V[1A#OCSN"NLB2(P5O>
M1MN]"6"L%=PV&B=1:IT_+-+ILR)WU594EC$L;["2C%3C#)N;# CAB#GC&6-8
M:RPG3>!XWK375&#'<-Q.!]WTM2!Y3( 3C%DR"FD2'DD2I<R6>1,F2CD>:3*.
M8Q'*]ZKSC=Y)'>261Y99&9Y))#EW=B69FP ,DDG"A5'@H P*\Z_OKK4KN>^O
M)3-<W#[Y'( R0 JJJCA515554<*H 'A7O>8UU*<4KB6 W%@3A,15>6))&Q$^
MJJYX7M:B)_"JJG;BE:"7IM]9.#>G'U!;OM-Z:WS3+I%C1S=>&H\>A4+K6HR"
MFRQDF<6P!DUE5B$-/A&#W"0AE(K>[/;7SXK$'X<_ ?#/PQZ<\^&?&KKOVQCT
M>?X-VZ/]R]7_ ./_ $V\5.?0$\9XQ].,YY^_A@'9/J@>DOUC;-UM9=2/31N)
M@\0;)IZ*VNEJX^)U KF=%D29EY48%FP;.R&,\<#U4D>:,86D:Z.]CG-<J#@D
MY!\,'G''F?$''J<5M78W]Q_H]0_HRL5<;^YJO]'U@N\H*TGP0?=2PW=U\HJP
M/C_'7NO<7@O=>*D8P,>&./E59'K8?O8_4W_L;5'^_CK3BA\#\OO/P]:UN_2A
M]574OI_ZOV?@NP];[$S:?G6>P\M@3,,)C;(D.'&QZ!3NC3$N[:N,LEQHCRM4
M(R"]IS>[T?W:BL5/E@^''G]"?#Y'P\O$&K6?VRCTQ_W@M[?^_P  _P Y^*G/
MP/Z?Y_/T\ZIO]67U+=8>H*#3H==:_P \PA=;FR@EFN:$Q]Z3TO65K8Z0?N.T
ML510K">IOD>U_;L\/+Z]GWZT\<^(R,'(R?/' ^OK]/$[9WI8_O>G2A_)7 _R
MI:<47P'U_O4_N*RK4:]:GJ2R_JVZFM;^G9H0IKV/09A21\P%6&<^)>[3MQJ*
M-6S'A16EK, III9=HY7$#%LSV*F;\BI;[:L2"<C\C\_'C/B/(\>./GUOJU>E
M?CG3CTM:(W%HZN>ECH;':+ =QVU3%=#FY R=8%GQ-H34 5Q!S09G9RH<F2CB
MR(T"VJ ODNBU(WB??I4D>GP^.?3/G^OSXJZCTCNMX'6=TOTYLCL1GW%J5E=@
M^T $,-9UF8,/M09H\#6#5@,I@1BO,]K5$MQ MQL<U!H-B@^>?O/UX(YJS^;4
MU5DYCK&LKY[A(K1NFPHTIPVN7NK6*<1%8BJB*J-[(JIW7Z\5-5@^L+CU#$].
M3J7D0Z2HBR!8YC*C/&K80##5<[Q=%5A1A8]BJU515:Y/HJI]47MQ0_?V*K4^
MS75%39:>ZG'V-77SWBV5A#1OFPHTIPVKB]BJM&XXB*Q%7ZN1JHBKV54[\?X^
M_P O#YYJ!YCT.,GQ/ \?OYULQ1L?H89F28E)419 U51GC5L,!AJYJM56%$%K
MV*K55JJUR*K55%^BKQ4U_)&/4$LQ)$NCIY,@J^13R*R$8Q'(B(BD*0#GO7LB
M)W<Y5[(B?J3BE:N_VE*IJZW$>E]U=6U\!Q<CSY"K"AQHJD1*RG5$(H!C5Z(O
MU1'=^R_EQY_G^WG]Y^E01YXYX_O\/+S]*MT])['J"7Z=O2O(E4=/)D&U]+<4
M\BLA&,5WZ69$GD0I .>]>R(G=SE7LB)^I.*#P'_OW\:L<A5-56*1U=65]>XR
M-0JPH4:(I48KE8A% ,:O1BN<K4=W1JN=V[=UXJ:U^?M'_P#J/=4?R_4_]!\V
MXJ"<??\ ;U/PJ0?H,=O]#CUOV_[^=H_^O]+YO\:_U^O;B@SY_P#O ^ _4?IB
MKD^*FM%;9/[_ #V7_GC4O_S]:O\ 7\__ *<5'G^7B?I^?R\?/'&=ZGBIK5^^
MTQN<FO.E)B*OB[,]FN5O=?%7-H\51JJGY*K4>Y$7\T1SD3\UXK%LXX&3_G]O
M7/EZ'!JTKTD<>H)?IR]*\F71T\J07!;9Q3R*R$8Q')FV4M1Q"D Y[U1J(B*Y
MRKV1$_)$XK(#%6+DQ/&'C>S]':%/-CF]_N>O7MY-5._;X_U[=^*@C/Y$9]*I
MD]/;T9ZSH8W<;>\K?UELK(SXKD6++01, C8?1"C9)(KI,@A#ERO)I\M\1]<-
M *BPV%5?-X6*B,10 C.3YGU\/3Q^7EQSZU=WQ4UHQ_:"GH/U"&$7NJ,TMK5[
MNWYJC;+*W*B?7LOT3Z?E]>*@^(^'P^!!Y^HX\\?4>SZA_43ZD/51VOBO25T^
MSZ[1^I<JE!I(U;D685^,S<V9 "YS[+.\B>2,YT0HAJ>'@E$Z<LDK0B<*[F"&
M02H\QC/R_/&<GS\? D8\JV#_ $__ $F-!=$-;7Y3+CP]K;W)$%]Y;0OJL; T
MAR!1)4+ J4YI@L>A(]Q!?>:D->30_P#/Y@ D=#8J0,?'Y^./3/G5K7%36"<M
MZB]:X5F0L(NI=FEHI8H)DN+!::LJS2T:X(Y\A9 SM5!D&0BQXLEHF$:XCFIY
M>- ]5_ZD_P -.C>N%Z!U>?5VU9);6#4+VSL89M)TB>\1)((M0N)+R&Y#&*6&
M60VEG=K%'*AD92&"[?I_1&NZGI1U>VCMQ;$2-#%)*R7%RL98,T""-D(W*RKW
M)8RS A0>*SJUS7-:YJHYKD1S7(J*CFJG=%14^BHJ+W14^BIR_597571@RL R
MLI#*RL,AE(R""""""00<BM1(()!!!!P0>""/$$>1%1T9TLZE9LA-G)6V/WRE
MHMVVM6?_ ,HFV[GJ59WP?9]Q7?(597L+)6/\C\:B5G[GRI(_P4Z(BZI/5:6]
MX+DWQU,Z>;A3IGM[.93/V>T)"AG/M!A,QC[^208SVJVX];Z\VD?P8S1>S]@6
MW>[9]J]G V]ON[MO]&(R^S?L&,[O>KV&\-M5>E-=V^=V<4EB^(\$&JJQO]IU
ME;S7.9#BN,J.0 $1A3R3>+E'' 51L(51C?N?6/4\'26B3ZM+"US+W([:TM@2
MHFNIMW;620 ]N)%1Y)7P3L0J@:1D4^5T_HLNO:G#IT3B(.&EFE(SVH(\&1PO
M&]N0J+D LPR0,D51UOJ3;:@9*&5?XYB-CB_RT673P(DR#8L@J7LYL:U)-DM=
M)&)>S'FAJ(A$;YL&U7=J2TS\6^IY9XY;F+39K<R R6R6\D),66]R.;O.R. 0
M!(RR LHRF":MR?\ #'1FMF2WN;V*ZV>Y/)(DD?< '+PB-?=+>*K(" >"2*FM
MU-Z/A]8NF\.O\"MHD*Z  658?*MD("#8U]S!&LJHLB1QR"Q'F:R.X4A@SLCR
MXZL>U0F(5EM:]I8ZOTC3-4TM@LPB%S;I.!'WX+A%+P2-M8QRHRJ8R6[6\.K$
M*_<30>F]:?H_6+ZUU"%GA9FM+Q8<-)%)"Y"31!B@=1EMRDJ61LC#*%-<&KO3
M*W1<YS5KM -%BN$0)X95T>/>0[BSM8D8B$=7U42M<=K235:@7RIIH@XX'D,U
M#E&R.3P=.Z2U=W2&YA6U@8;9YFFC=D0 !DB6)V9Y7!PC K$OO-W=R*DF^:I^
M(FC16<ATYIKN\92($,#Q1(YR \SRA?=3D[$5F8@+A58NLW>NWK/L^EN#B^#Z
M\J:Z=G605*V89=T,DJJH*"*8E=',^((H23ITN1%., G&&((X[RF\_<$QV]:E
M?S6TL-A:8C(B5Y;A@'9(\F-(XE8%#,0C.SR96,=L]N02'9I'1W2D?4+7-[?R
M2+:0R]K9"0DDT[ 2/[Q!V(BNI.%)8M@%=O,0NE#U0=DY5MG&M=;NAX_:4N;V
ML3'ZK(:*K2GGTUW9F;&JTEQA')%G0)<P@(3_  &"1'4S#(XR(YBXV=Q>VZQ]
MZZEOXVD17::* 7"B5@H9#:06\95&*Y5H<[-S&3@8V3J3H#3[?3KB]TDRP2VD
M3SR022M+'+%&I:3:SY='"AG!+,IQMP,C%O\ O716O>HO7ECK+9E=*GX[/EP[
M$1:^6L"TJ[6O4BPK.LFHPJ1Y@&&.%5>(PBQI,B.81 F>Q??="S1NK,DD,G=B
M=<$J^QXSE6!5E9)'1E(Y#$@A@&%8Z1JUYHMXM]8NJS*C1LLB[XY(WQNCD7()
M4E5;A@0RJP((KSW3CTRZMZ6L*F8/JV#9B@6EL2]N;*[G_>=Q;6A(X(B'ERF@
MC!:($6,$$:-&C  %C7.\'&*8I)P[R--,_=G=41Y"JK[D>[9&B@>Y$C/(ZIEL
M-)(Q8LQ)YM;UV_U^Y2YOVCW11B**.)-D4:9+'"DL2S$Y=F8DX X55 \MU4=9
M>E>CZDQJYV[-OE)ETV;"Q^EQ>I'<74_[L9%)92TCGFU\8$*"V;$0TB1,%Y$D
M#$!IBJK$[%O;75Y*T%E;27<R1B62.)[>,QQLQ57=KF:"-0[*P0%]SE'VJ0CX
M[&@=,ZGU)+/'IX@5;=4,LUS(T<2ER0B I'*S.VT\*AP!EBH(SF/4.VL'WGKC
M%MJZXM77.&YA!).IYQ(Y(A^T>4>!,BRXID0D:; GQ94*9'?W44F.5GDY&HY<
M)(Y89'BGB>&:-BDD4@ =&4X(."5(\PR,R."&1F4@GS-2TZZTJ]GT^]01W-LP
M6158,IW*KHRL/ZD=&5U.!E6&0#Q62>85T:<4KP6U,[#J[66P=E2:F=?1M?X7
MDV:2:6L>)EC:Q\9IIER>O@O-W$V7*##>$"D16(1[?)%3Z<4K76TIZC/I;=85
M_LC,^K+IYZ>].W5?8U \<G[-H:;.LHS8$N/+=86,ZSBX5&:TL$@8XGM>IWN6
M1]3D1J/5X5'!\@<?(_?'/K4A/V6/L_?_ '+Z-_YJH'\/;\DQ3O\ Q_ZW%./(
M?+&/S'YX^OH<U1]ZR>6>GYE#>G].AB)IN,Z&[9'[)/[$N* QE7I(3"OT52\]
MBIK/F^*BO_N]'>_['E,[>VI7>:H) ]!X^G)!!]#Y^/GGRK<QZ8ARA=..AQS6
ME9*9J'7;3M.CD*UZ8I5?0B/_ !([MV_/Z]NW%9"H0>MA^]D=3?\ L;5'^_CK
M3BH.?*JK?L]>B=+;9T-OBTV?JC7VP;*KV[6U];/S'$J3(I<""_#:F0^)$D6D
M*26/&<<CS."-S1J5[GJWR<J\4&?/_KZ9Y_QX>5;!O]AETD?X-.C?I_XL<0__
M !/U_P#3R,?/GXG['TJ:UG_M#VE]1:EA]-3M7ZSP77KKF3GB6SL-Q>GQU;)(
MHJ18R3EJHD59* 4A%"AO-!J]ZM[>2]\O_/\ /]_7YUB1D\9S@?+SQ]?C@X\1
M5_'I8?O>G2A_)7 _RI:_U_X/RY%%_I'WY_(5VOJ*]8%+T5],&;[5,>*3-9X'
M8IJ^F.0:/M\YN %'7O\ 9<]KS0Z0#9%[9(-%7XD!PE5BF:]%2? _?ZX./OYU
MI\]&W15ZF^WSQ^L[IGA/AW=[?Y<RNVA<YGA^/9!:VDLTB%E5K5BRJ0R0<$J5
M*GUQ;:-']I\@=A# 9' .QJL5\L<_$Y\?4>O.?'!Y/D>9_9ITD_:"]B8ID&#9
MOG1LFQ'*JN72Y#C]MMO5$JNMJN:)12H4L#C]B!,Q51414<U41S7-<U'(K+GY
M>'AC]QY??I4">D;8VZ?2%Z\JO&=\4LW%*FT%4XON+'HLZ':UME@N2^U(K<IJ
MIT$Y:VV_1V8\=M#DQ9#FN=$LZWW0D*96/O[^_P!ZQR1Y9Y.?AGPP>./7\_#!
MK?8J[2NNZVON:B;'L:JUA1;&ML(A6'BS8,T+)$27&,Q584$@!&%$1JJUS'(J
M+V7BLZK8]8[][=ZFO]K>,_T\Q;^O\7Y\5!\#\C59GV:'_K.]4'\I>#?T6LN*
M#YY_Q]^=;-/%33BE:M_VE_\ ZD.EO_;)G_\ DNFX\_S_ &J",_9_:K?/26_>
MYNE/^3V7_2W(^*#P'RJQ3BIK7O\ M'H#/Z-]72&#>X .H"B88J-56"<?!\Y0
M2/<B=F^XHWHWO^:M5$[\5!&<>/CY>7CS6-?1Z]0'HZZ?^AS!M:;AWMB&"9S6
MY=L&?/QVW2U6;'B6V32IE<<BQ*Z2#PE17L*/L55\53R1J_3B@/B/3CT\JM#_
M -%K].K_  J->?\ LW_\7_@;^/\ Q+Q3/T^>/C_C/V:U0@YQBNY?6XJ\^UE<
MQLOQ#,>K"EO,9O*QAUB6]2LJ&7YT9I@B/[/M@,_N03'(T;E<B(G?BH(R1X_M
MQ@_D<8^?EYG?4XK*M83[3#%._6G2M-:-RQ09SL>,4R-56,/*H,<+'&YW;LCB
M#AR7-:J]W()ZIW1KNRH/ ^_T^GZ9X/@<_P#IJ>I!T1Z=Z&>G;6>R^H7"L1SK
M$L0LH&18Y9)<?.JIALMR&<,$A8]88'F^)+CG3VRO3P*WZ]^Z(J<_EZ_O4XB^
MK7Z=GMD\.JC7OGX/\>S;[OY(U?'MWI_UKV[?P\5!\#ZXX^P?O/C5-7HR^H]U
MB=2/54?2.XMF?LC:[CZ[S/)F%M,8QT%Y"ETLRFCU1'9'4U==820O^\",(VT+
M-*97-[$:K.*#/GD\GQQ]_P!O+CQK:OXJ:T9/M!"([U"A-5$5%TQK1%1?JBHM
MGE:*B_3\E3Z+^?%0>/7&#GZ?7^WYC%63>H'Z%=7F,%^\NB4$+#<[%$C7E[IQ
MLHE90W\YHFRCV.O[#R\,:O7%\2BHRNCTLDODZ#*JBH,!E1CCCT^1\O+P\O#@
M>7@34;NA;UJ]O],N2BZ<>O>ES.YH,:FLQAN:7-9)%M'7+X7>(R'E];/;'FY9
M3Q7-&U\TCUR")#:I@/NQH"-Q09^!^//AQS\_@!CX@^.V?KK9.!;;P^ES_6F6
M46;8=D,1DVHR#'K"/8U\L+T^K?= ]WLR0O\ (4J(=!2HIV$!("(S'L1658FS
M;IBP3.LY;G%G-N(YI!HLBVJXI@I$LS0V"$)RE>)TB*TH@B%):)SO-C54+H[W
M>:?,W6G^EKH;K;\03U_?:CK-K->3VEUK6DVTD)M=4N+&.&&%DN)$:>Q22&W@
MBN4AW[U0F%K>1RXWG2^OM7TK1_X1!%;.L:R):W#JW<MUD9F8;0=DA5G9HRP&
MTGWPX %2.8QHV-&QJ-8QK6,:B=D:UJ(UK43]2(B(B)_ G/I:-$B1(XU"1QHJ
M(BC"JB *JJ/(*H  \@*T<DDDDDDDDD^))Y)/Q)K'C=MZV?F'Z MS&D7+O<4"
M4J2F_)64B>2PT=V]E9J-17?$0BR.R*OM_1>:BG7_ $?)U">EDUZR;7 W;-FK
M.?YX.#:B?9[.;L>)MA*9@.=E>L= U@:?_%3I]R+#&[VDH=FS_P#9C^KM<@=S
M&S)'-8_ZG]0S]U:FML2I3A!?QID.\HDDO046585Z&:D&29>Z '+CR#B:=45!
M']E[_P!S1_.K^(G3%QU5T[)8V3(+ZVN(KVT20JJ3R1!T:W:1B!%W(Y&VR'@2
M*@;",Q'?Z2UN+0=9BO+A6:V>-[>XV#+I'+M/=5?%BC*I*<%EW >]BJ3H'1[U
M$7^3#QQ-;W=4XLI(\BYMQLB44,7N=B2RVBO='-'&Q'D;\5T@AT;X1Q&>]K7?
M/>D]%=5M-%:G0K^&5I.V7N(6A@B]Y@9))WQ&D8 +!PS;QCMJY90UY3]9=-P6
MS7/\5MI0$WK#"Q>X<XX180-X8D@'>%"G)8@ D6L[DV_5=$V@\#H8,1,JR&+6
M0L1Q>'*(^-&EGJX#'3[>Q>)%(R#%5S'>P)6F.20 #'L;[IA?0>H:DW1F@Z3I
ML6V\ONPMK"\JL(08(P9KB54*DH'9$2(,CR;N& 1R*>TC2)>M=>U"YD8VELTD
MEY=.F&=5EDQ'#'NX,CC/OL"JA68@Y53!;5?JEYZ[.*NNVYC.($PVTG!A3+'%
MH-I66=$R21HV3_"=<6H+"-&<Y'2(SFQSJ'S>R0KFM8_RM.ZRU/N))>K;36QR
MTZQ1&&2->-SP.9"I2, MVI5=WR5[X*XK<-4_#;3Q:2OI=Q=K=QJ6C2YDCEBF
M*@GMG9#$R,_ 5QD XRF"2,U^HQT@9QU LQ7:&J AO<BQZA)2V6-.E B'MZ-T
MB3:PIU.64\0#3P&F2!DA$*-\H! _&\C"41=LU2TF:>/4+:-IX6A43Q1)F8!
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M.!-]WY<-E>-C8[8TCWS>\%&(-Z%(CFJCE[J5B/\ L3NF7^\-JK_X*H_^)\C
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HBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g339043g76w73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339043g76w73.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $ZB^4#(X0DE-! 0      %D< @   @  ' )0  AR<C,Y,#DX,AP"!0!
M36EC<F]S;V9T(%=O<F0@+2!35%1+("T@,C R,B!0<F]S<&5C='5S(%-U<'!L
M96UE;G1?051-7U]'1$,@-RXR-@ X0DE-!"4      !!8!2,47&>'*?0<B?%A
M#5L>.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,]    !@
M           !(0  !.@    $ %, 5  P #$    !
M      $             !.@   $A                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "24    !    H
M "4   '@  !%8   "0D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "4 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&2,R-CE8<9>AUAHD4E17=Y2UT3,W.$16<G:1L;2WU6%E9W1U>(&6HK+3_\0
M' $!  $% 0$               4! @,&!P0(_\0 .A$  @(! P,!!0<#! $$
M P   0(  P0%$1(&$R$Q!R)!4? 4,F%Q@:'1D;'!%2-2X0@D,T+Q%K+"_]H
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M?U'O72E !*C=(M<:/)"(X##T5FCQE"9C2B(QR96J.80;FO:J+V5JHJ<1R?\
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MMO[VS'7/23H[![^KJK/(&8WCOZC\CSC-9V/T$TD5]W9OK\AKHS7%"@I,D46
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M+ZA_ZZ'/57_KXF-?O#\O_P"9O4\3+'W<1-&'1O\ 'ZI_\VFT/_UR[B8A]_\
M5O\ ,WGN)EE&?Y0I_%^%_P \VN_^[Y%Q+']!^?\ @SBOR=[_ (!UG_GKS?\
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MU/96H+A.AW^S_)JZ9JZ@7.KL9\&G47Q.V0%QKJTN4+;R/*U:W5G4HH!W4$[
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MFVI[.#,BENW<MC6<JV"D$KLRG8@[>Z9\]7/196]2)ZS*:2^#B^=5D-E:Z9,
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M+F]([TY3E>9_2M@"/(Y7N0<K* C15^_P$&_8(;?T-8QK4_!$XEO%?E_>>O\
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MV$5&$5CG-1=>Z>ZQT'J=LBO2LFQ[L8![*<C'NQ;C26""]*[T1GI+L$YKN Q
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M*)S7C@0VN&V1)7X:\HV-:YSE1$3,U5:5]W65]Q52PSJRTA1K"OFQGH2/*AS
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M/A5W4;F2ZNZF3J3)Q7IQ6QJ,2IDK%K*]SM8W)V<H.( /NJH)\;D^3)%9YLG
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+B(XB.(CB(XB?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
